Cargando…

Preliminary results of proton radiotherapy for pediatric rhabdomyosarcoma: a multi‐institutional study in Japan

To evaluate preliminary results of proton radiotherapy (PRT) for pediatric patients with rhabdomyosarcoma (RMS). From 1987 to 2014, PRT was conducted as initial radiotherapy in 55 patients (35 males, 20 females, median age 5 years, range 0–19) with RMS at four institutes in Japan. Thirty‐one, 18, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Mizumoto, Masashi, Murayama, Shigeyuki, Akimoto, Tetsuo, Demizu, Yusuke, Fukushima, Takashi, Ishida, Yuji, Oshiro, Yoshiko, Numajiri, Haruko, Fuji, Hiroshi, Okumura, Toshiyuki, Shirato, Hiroki, Sakurai, Hideyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943484/
https://www.ncbi.nlm.nih.gov/pubmed/29605967
http://dx.doi.org/10.1002/cam4.1464
_version_ 1783321636788764672
author Mizumoto, Masashi
Murayama, Shigeyuki
Akimoto, Tetsuo
Demizu, Yusuke
Fukushima, Takashi
Ishida, Yuji
Oshiro, Yoshiko
Numajiri, Haruko
Fuji, Hiroshi
Okumura, Toshiyuki
Shirato, Hiroki
Sakurai, Hideyuki
author_facet Mizumoto, Masashi
Murayama, Shigeyuki
Akimoto, Tetsuo
Demizu, Yusuke
Fukushima, Takashi
Ishida, Yuji
Oshiro, Yoshiko
Numajiri, Haruko
Fuji, Hiroshi
Okumura, Toshiyuki
Shirato, Hiroki
Sakurai, Hideyuki
author_sort Mizumoto, Masashi
collection PubMed
description To evaluate preliminary results of proton radiotherapy (PRT) for pediatric patients with rhabdomyosarcoma (RMS). From 1987 to 2014, PRT was conducted as initial radiotherapy in 55 patients (35 males, 20 females, median age 5 years, range 0–19) with RMS at four institutes in Japan. Thirty‐one, 18, and six patients had embryonal, alveolar, and other RMS, respectively. One, 11, 37, and six patients were in IRSG groups I, II, III, and IV, respectively, and the COG risk group was low, intermediate, and high for nine, 39, and seven patients, respectively. The irradiation dose was 36–60 GyE (median: 50.4 GyE). The median follow‐up period was 24.5 months (range: 1.5–320.3). The 1‐ and 2‐year overall survival rates were 91.9% (95% CI: 84.3–99.5%) and 84.8% (95% CI 75.2–94.3%), respectively, and these rates were 100% and 100%, 97.1% and 90.1%, and 57.1% and 42.9% for COG low‐, intermediate‐, and high‐risk groups, respectively. There were 153 adverse events of Grade ≥3, including 141 hematologic toxicities in 48 patients (87%) and 12 radiation‐induced toxicities in nine patients (16%). Proton‐specific toxicity was not observed. PRT has the same treatment effect as photon radiotherapy with tolerable acute radiation‐induced toxicity.
format Online
Article
Text
id pubmed-5943484
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-59434842018-05-14 Preliminary results of proton radiotherapy for pediatric rhabdomyosarcoma: a multi‐institutional study in Japan Mizumoto, Masashi Murayama, Shigeyuki Akimoto, Tetsuo Demizu, Yusuke Fukushima, Takashi Ishida, Yuji Oshiro, Yoshiko Numajiri, Haruko Fuji, Hiroshi Okumura, Toshiyuki Shirato, Hiroki Sakurai, Hideyuki Cancer Med Clinical Cancer Research To evaluate preliminary results of proton radiotherapy (PRT) for pediatric patients with rhabdomyosarcoma (RMS). From 1987 to 2014, PRT was conducted as initial radiotherapy in 55 patients (35 males, 20 females, median age 5 years, range 0–19) with RMS at four institutes in Japan. Thirty‐one, 18, and six patients had embryonal, alveolar, and other RMS, respectively. One, 11, 37, and six patients were in IRSG groups I, II, III, and IV, respectively, and the COG risk group was low, intermediate, and high for nine, 39, and seven patients, respectively. The irradiation dose was 36–60 GyE (median: 50.4 GyE). The median follow‐up period was 24.5 months (range: 1.5–320.3). The 1‐ and 2‐year overall survival rates were 91.9% (95% CI: 84.3–99.5%) and 84.8% (95% CI 75.2–94.3%), respectively, and these rates were 100% and 100%, 97.1% and 90.1%, and 57.1% and 42.9% for COG low‐, intermediate‐, and high‐risk groups, respectively. There were 153 adverse events of Grade ≥3, including 141 hematologic toxicities in 48 patients (87%) and 12 radiation‐induced toxicities in nine patients (16%). Proton‐specific toxicity was not observed. PRT has the same treatment effect as photon radiotherapy with tolerable acute radiation‐induced toxicity. John Wiley and Sons Inc. 2018-03-31 /pmc/articles/PMC5943484/ /pubmed/29605967 http://dx.doi.org/10.1002/cam4.1464 Text en © 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Cancer Research
Mizumoto, Masashi
Murayama, Shigeyuki
Akimoto, Tetsuo
Demizu, Yusuke
Fukushima, Takashi
Ishida, Yuji
Oshiro, Yoshiko
Numajiri, Haruko
Fuji, Hiroshi
Okumura, Toshiyuki
Shirato, Hiroki
Sakurai, Hideyuki
Preliminary results of proton radiotherapy for pediatric rhabdomyosarcoma: a multi‐institutional study in Japan
title Preliminary results of proton radiotherapy for pediatric rhabdomyosarcoma: a multi‐institutional study in Japan
title_full Preliminary results of proton radiotherapy for pediatric rhabdomyosarcoma: a multi‐institutional study in Japan
title_fullStr Preliminary results of proton radiotherapy for pediatric rhabdomyosarcoma: a multi‐institutional study in Japan
title_full_unstemmed Preliminary results of proton radiotherapy for pediatric rhabdomyosarcoma: a multi‐institutional study in Japan
title_short Preliminary results of proton radiotherapy for pediatric rhabdomyosarcoma: a multi‐institutional study in Japan
title_sort preliminary results of proton radiotherapy for pediatric rhabdomyosarcoma: a multi‐institutional study in japan
topic Clinical Cancer Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943484/
https://www.ncbi.nlm.nih.gov/pubmed/29605967
http://dx.doi.org/10.1002/cam4.1464
work_keys_str_mv AT mizumotomasashi preliminaryresultsofprotonradiotherapyforpediatricrhabdomyosarcomaamultiinstitutionalstudyinjapan
AT murayamashigeyuki preliminaryresultsofprotonradiotherapyforpediatricrhabdomyosarcomaamultiinstitutionalstudyinjapan
AT akimototetsuo preliminaryresultsofprotonradiotherapyforpediatricrhabdomyosarcomaamultiinstitutionalstudyinjapan
AT demizuyusuke preliminaryresultsofprotonradiotherapyforpediatricrhabdomyosarcomaamultiinstitutionalstudyinjapan
AT fukushimatakashi preliminaryresultsofprotonradiotherapyforpediatricrhabdomyosarcomaamultiinstitutionalstudyinjapan
AT ishidayuji preliminaryresultsofprotonradiotherapyforpediatricrhabdomyosarcomaamultiinstitutionalstudyinjapan
AT oshiroyoshiko preliminaryresultsofprotonradiotherapyforpediatricrhabdomyosarcomaamultiinstitutionalstudyinjapan
AT numajiriharuko preliminaryresultsofprotonradiotherapyforpediatricrhabdomyosarcomaamultiinstitutionalstudyinjapan
AT fujihiroshi preliminaryresultsofprotonradiotherapyforpediatricrhabdomyosarcomaamultiinstitutionalstudyinjapan
AT okumuratoshiyuki preliminaryresultsofprotonradiotherapyforpediatricrhabdomyosarcomaamultiinstitutionalstudyinjapan
AT shiratohiroki preliminaryresultsofprotonradiotherapyforpediatricrhabdomyosarcomaamultiinstitutionalstudyinjapan
AT sakuraihideyuki preliminaryresultsofprotonradiotherapyforpediatricrhabdomyosarcomaamultiinstitutionalstudyinjapan